Provision of medical communication and medical liaison services within biopharmaceutical companies have existed in one form or another for about 50 years. Over the years, these services have been introduced to countries areas across the globe. With popularity comes the potential for regulation. This session will review some of the different types of medical communication and medical liaison models, review related regulatory guidelines in place, and discuss the implications for the globalization of medical communications and medical liaisons.